

4 Med 32 247 (22,3)

# TRANSPLANTATION PROCEEDINGS

An Official Publication of The Transplantation Society  
The Japan Society for Transplantation • The Hellenic Transplantation Society  
The European Society for Transplantation • The Canadian Transplantation Society  
The Transplantation Society of Australia and New Zealand  
The Scandinavian Transplantation Society • The Latin American Transplantation Society  
The Pan-American Society for Dialysis & Transplantation • The Society for Organ Sharing  
The Catalan Transplantation Society • The Asian Transplantation Society

VOL XXII, NO 5

OCTOBER 1990

## CONTENTS

7299 - 1954

### PROCEEDINGS OF THE SEVENTH SCIENTIFIC CONGRESS OF THE TRANSPLANTATION SOCIETY OF AUSTRALIA AND NEW ZEALAND

#### Basic Mechanisms and Xenografts

Antibody-Induced Rejection of Long-Term, Functioning Pig Proislet Xenografts in CD4 <sup>+</sup> T-Cell-Depleted Diabetic Mice .....	<i>C.J. Simeonovic, R. Ceredig, and J.D. Wilson</i>	2091
The Effect of Continuous Anti-CD4 Monoclonal Antibody Therapy on Fetal Pig Pancreas Xenografts in Nonobese Diabetic Mice .....	<i>T.E. Mandel and M. Koulmanda</i>	2093
An Analysis of Concordant Xenograft Rejection in the Nude Rat Model ....	<i>S.M.L. Lim, A. Wee, S.M. Chong, and D.J.G. White</i>	2095
Enhancement of Rabbit Skin Allograft Survival by Pretransplant and Peroperative Hepatic Antigen Treatments	<i>S.V. Mitchell, L.J. Dumble, R.J. Plenter, R.J. Millar, and G.J.A. Clunie</i>	2097
Adhesion of Lymphocytes to Stimulated Vascular Endothelial Cells Occurs Via ICAM1-Dependent and ICAM1-Independent Pathways .....	<i>R.J. Faull and G.R. Russ</i>	2099
The Importance of the ICAM-1/LFA-1-Dependent Pathway in In Vitro Cytotoxicity Against Cultured Human Kidney Cells .....	<i>M.G. Suranyi, G.A. Bishop, C. Clayberger, A.M. Krensky, P. Leenaerts, and B.M. Hall</i>	2101
Characterization of the Rat CD26 Antigen .....	<i>G.W. McCaughan, J. Wickson, and M.D. Gorrell</i>	2103
A Model of the Corneal Allograft Reaction ..	<i>I.G.M. Duguid, R.A. Cuthbertson, R.H. Guymer, K.A. Williams, and T.E. Mandel</i>	2105
Prolongation of Heterotopic Human Corneal Graft Survival in Mice Treated With an Anti-CD4 Monoclonal Antibody .....	<i>I.G.M. Duguid, M. Koulmanda, and T.E. Mandel</i>	2107
The Effect on Researchers of Handling Human Fetal Tissue .....	<i>B.E. Tuch, S.M. Dunn, and V. de Vahl Davis</i>	2109

#### Immunosuppression

Immunosuppression by Anti-CD8 (Ly-2.1) MAb Conjugated to Idarubicin: Studies in the Mouse Heart Graft Model .....	<i>P.L. Mottram, G.A. Pietersz, L.J. Purcell, G.J.A. Clunie, and I.F.C. McKenzie</i>	2111
Prolongation of Fetal Pancreas Allograft Survival in Mice Treated with Anti-IL-2 Receptor Monoclonal Antibody (PC61) Conjugated with Idarubicin .....	<i>M. Koulmanda, G. Pietersz, I.F.C. McKenzie, and T.E. Mandel</i>	2113
Beneficial Effects of Monoclonal Antibody Targeting of CD4 <sup>+</sup> Cells During the Sensitisation but not Effector Phase of Accelerated Rejection of Rat Cardiac Allografts .....	<i>W.W. Hancock, T. Sablinski, E.L. Milford, N.L. Tilney, R.C. Atkins, and J.W. Kupiec-Weglinski</i>	2115
Castanospermine, an Alpha Glucosidase Inhibitor, Prolongs Renal Allograft Survival in the Rat	<i>P.M. Grochowicz, A.D. Hibberd, K.M. Bowen, D.A. Clark, W.D. Cowden, C.R. Parish, and D.O. Willenborg</i>	2117

CONTENTS

Urocanic Acid in Allotransplantation ..... *R.H. Guymer and T.E. Mandel* 2119

The Interaction of IL-2 and IL-4 With the Effects of Deoxyspergualin ..... *P.G. Kerr and R.C. Atkins* 2121

The Effect of 2-Deoxyguanosine on Graft Immunogenicity ..... *H.M. Georgiou and T.E. Mandel* 2123

FK 506 and Orthotopic Liver Transplantation in the Rat ..... *H. Isai, D.M. Painter, and A.G.R. Sheil* 2125

**Renal Transplantation**

A Prospective Study of the Effect of Diltiazem in Renal Allograft Recipients Receiving Cyclosporine A: Preliminary Results ..... *J.J. Kelly, R.G. Walker, A.J.F. d'Apice, and P. Kincaid-Smith* 2127

Elimination of Nonimmunological Causes of Cadaveric Renal Allograft Loss—An Attainable Goal? *R.D.M. Allen, J.R. Chapman, A. Akinoglu, T.G. Wilson, S. Lawrence, D.C. Harris, A.J. Richardson, H. Lau, and J.H. Stewart* 2129


Kidney Preservation With UW Solution: The Nature of the Impermeable Membrane ..... *V.C. Marshall, P. Jablonski, B. Biguzas, B.O. Howden, and K. Walls* 2131

Comparison of Serological Class II Typing With DNA-DR and DNA-DQ Typing of Kidney Donors and Recipients ..... *J. Trejaut, H. Dunckley, J.S. Sullivan, T. Doran, and J. Chapman* 2133

Serial Monitoring Shows Plasma Protein C and Free Protein S Levels Are Decreased During Human Acute Renal Allograft Rejection .... *A. Tsuchida, N.M. Thomson, H.H. Salem, R.C. Atkins, and W.W. Hancock* 2134

Inhibition of PHA Lymphocyte Responses by Cyclosporine and Methylprednisolone ..... *M. Hibbins, R.D.M. Allen, and J.R. Chapman* 2137

Increased Frequency of Kidney Allograft Rejection in Recipients With Cyclosporine and/or Steroid-Resistant Lymphoid Responses ..... *L.G. Bowes, L.J. Dumble, D.M.A. Francis, I.M. Macdonald, G.J.A. Clunie, and P. Kincaid-Smith* 2139



**Cardiac Transplantation**

Heart/Lung Transplantation in Australia: Early Results of the St Vincent's Program *P. Spratt, A.R. Glanville, P. MacDonald, A. Farnsworth, D. Bryant, A. Keogh, and V.P. Chang* 2141

Cells Infiltrating Heart Allografts: Specificity and Function ..... *C. Farrell, C. Hoadley, M. Honeyman, S. Fussell, P. McDonald, and J.R. Chapman* 2143

**Hepatic Transplantation**

Determinants of Successful Liver Transplantation ..... *A.G.R. Sheil, J.F. Thompson, G.W. McCaughan, S.F.A. Dorney, M.S. Stephen, A. Shun, M.J. Bookallil, H. Isai, J. McDonald, V.L. Harrison, N.D. Gallagher, D.M. Painter, K. Rickard, F. Hawker, T.J. Doran, and G. Kyd* 2144 ✕

<sup>31</sup>P-Magnetic Resonance Spectroscopy in Evaluating Hepatic Function: A Possible Application in Donor Assessment Prior to Liver Transplantation ..... *H. Matsunami, H. Hirose, A. Onitsuka, S.V. Lynch, G.A. Balderson, and R.W. Strong* 2146 ✕

Complications of Sclerotherapy for Esophageal Varices in Liver Transplant Candidates ..... *P. Pillay, T.E. Starzl, and D.H. Van Thiel* 2149 ✕

A Comparison of UW Solution With and Without Hydroxyethyl Starch for Liver Preservation Using the Isolated Porcine Liver Perfusion Model ..... *H. Isai, A.G.R. Sheil, R. Bell, K. Woodman, D.M. Painter, J. Earl, P.D. Kirwan, and W.G. Liu* 2152 ✕

Glucose Homeostasis in the Rat After Liver Transplantation ..... *P. Jablonski, C.W. Cham, B.O. Howden, A.C. Thomas, and V.C. Marshall* 2154

# Quadruple-Drug Induction Therapy in Combined Renal and Pancreatic Transplantation—OKT3 Versus ATG

W.-D. Illner, J. Theodorakis, D. Abendroth, S. Schleibner, M. Stangl, R. Landgraf, and W. Land

THE pancreatic allograft rejection remains a major problem in pancreas transplantation. Despite the introduction of cyclosporin and other new immunosuppressive drugs, the incidence of rejection episodes range from 30% to 80%.<sup>1,2</sup> We present here our experience with quadruple-drug induction therapy consisting of CS, azathioprine, "high" doses of steroids and antithymocyte globulin (ATG) or OKT3 for a short period of time.

## PATIENTS AND METHODS

In a controlled prospective study (March 1988 to July 1989), 20 diabetics were grafted simultaneously with a pancreas and a kidney. We used the occlusion technique in six patients and the bladder drainage in four patients in each group. Recipients' criteria and number of HLA mean mismatches in both groups were comparable.

### Immunosuppressive Protocol

In 10 patients (group I) in addition to triple-drug therapy ATG in a dosage of 4 mg/kg body weight was used. In group II, OKT3 (5 mg/d) was added to the standard regimen. ATG and OKT3 were given for 10 days (Table 1).

### Antirejection Therapy

The first rejection episode was treated with 250 mg methylprednisolone for 3 days. The second and third rejection crises were treated with ATG or OKT3 for 7 days. Patients that received ATG as induction therapy were treated with OKT3 and vice versa.

**Table 1. Quadruple-Drug Induction Therapy in Pancreatic Transplantation (ATG vs OKT3)**

Cyclosporin	1 mg/kg body weight for 24 h per infusion (blood levels, 100 ng/mL), switch to oral medication as soon as possible (6-10 mg/kg body weight)
Azathioprine	1-2 mg/kg body weight/d
ATG	4 mg/kg body weight for 10 d
or	
OKT3	5 mg/d for 10 d
Steroids	500 mg intraoperatively, reduced to maintenance dose of 30 mg/d within 1 wk

## RESULTS


In total a pancreatic allograft rejection was observed in 10 of 20 patients (5 in each group). In both groups one pancreatic graft was lost due to an irreversible rejection. A second pancreatic graft loss for an unknown reason was observed in the OKT3-treated group (Table 2).

Kidney graft rejection was observed in four patients in the ATG group and in five patients in the OKT3 group. All

From the Division of Transplant and Surgery, Departments of Surgery and Urology, Klinikum Grosshadern, and Department of Internal Medicine Innenstadt, University of Munich, Munich, FRG.

Address reprint requests to Dr W.-D. Illner, Division of Transplantation Surgery, Klinikum Grosshadern, Marchioninstrasse 15, 8000 München 70, FRG.

© 1990 by Appleton & Lange  
0041-1345/90/\$3.00/+0



**Fig 1.** Pancreatic graft survival probability estimated by Cuttler/Ederer using ATG or OKT3.

**Table 2. Pancreatic Graft Losses**

	ATG	OKT3
Total	2	3
Immunological failure	1	1
Patient death*	1	1
Unknown		1

\*None of the patients' death was due to the immunosuppressive protocol.

kidney graft rejection episodes were reversible with antirejection therapy.

Six of 20 patients showed a parallel rejection episode in both organs (three in each group). The rate of infection complications was 60% in the ATG group and 40% in the OKT3 group (one life-threatening event in each group). One patient death (arrosion bleeding) occurred in each group.

Patient and kidney survival probability rate is 90% in both groups. Pancreas survival probability is 60% in the OKT3 group and 80% in the ATG group. The difference is not statistically significant (Fig 1).

## CONCLUSIONS

1. Quadruple-drug induction therapy using ATG or OKT3 provides an effective immunosuppression with excellent graft survival and function.
2. In our study the use of the monoclonal antibody OKT3 did not provide an advantage over the use of a polyclonal antithymocyte sera regarding rejection episodes.
3. The infection rate was high, but did not differ in either group.
4. The small number of patients in each group does not allow final conclusions as to whether or not monoclonal antisera are better than polyclonal antisera. Both sera are optimal for treatment of acute rejection episodes.

## REFERENCES

1. Sutherland DER, Goetz FC, Mondry KC, et al: Diabetes Nutr Metab 1:57, 1988
2. Brattström CH, Tyden G, Reinholt FP, et al: Diabetes, 38(Suppl 1):57, 1989